Tier 4 — mechanistic

Structural and molecular aspects of betaine-GABA transporter 1 (BGT1) and its relation to brain function

Stefanie Kickinger, Eva Hellsberg, Bente Frølund, Arne Schousboe, Gerhard F Ecker, Petrine Wellendorph
Neuropharmacology 2019 161:107644

Bibliography

PubMed
PMID 31108110
DOI
10.1016/j.neuropharm.2019.05.021
Funding
Indexed grant support: W 1232 — Austrian Science Fund FWF — Austria. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignNarrative review
ModelEvidence synthesis; mixed research models
SamplePublished literature; no newly enrolled participant cohort
InterventionReview of betaine-related evidence; no single assigned intervention
DurationEvidence review; source-specific study durations vary
EndpointsBetaine biology; Clinical and mechanistic evidence

What the study showed, in plain terms

Published in 2019, this source examined mechanistic and clinical reviews. Its evidence base was Published literature; no newly enrolled participant cohort. It evaluated Review of betaine-related evidence; no single assigned intervention across Evidence review; source-specific study durations vary.

Reviews BGT1 structure, function and experimental inhibitors, highlighting uncertainty about its brain role.

Drug-target and transporter findings should not be relabelled as evidence that oral TMG controls seizures.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • Reviews BGT1 structure, function and experimental inhibitors, highlighting uncertainty about its brain role.
  • The recorded outcome domains were Betaine biology; Clinical and mechanistic evidence.

What this study can and cannot tell us

  • Drug-target and transporter findings should not be relabelled as evidence that oral TMG controls seizures.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Betaine: A Promising Natural Product for Neurological and Psychiatric Diseases
Ying Zhang et al. · Current neuropharmacology · 2026
Tier 4
Association of trimethylamine oxide and its precursors with cognitive impairment: a systematic review and meta-analysis
Caiyi Long et al. · Frontiers in aging neuroscience · 2024
Tier 2
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients
D Knopman et al. · Alzheimer disease and associated disorders · 2001
Tier 4
Global DNA hypomethylation and its correlation to the betaine level in peripheral blood of patients with schizophrenia
Yui Murata et al. · Progress in neuro-psychopharmacology & biological psychiatry · 2020
Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024
Tier 4
Beneficial Effects of Betaine: A Comprehensive Review
Madan Kumar Arumugam et al. · Biology · 2021

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology